The Clinical value of detecting peripheral blood T lymphocyte subsets and NK cells in patients with high-risk HPV infection

Abstract

Objective To investigate peripheral blood T lymphocyte subsets and NK cells in patients with high-risk HPV infection and different cervical lesions and its clinical value. Methods 126 cases of patients with 31 cases of patients with stage Ⅰ, 56 cases of patients with stage Ⅱ, 73 cases of patients with stage Ⅲ of cervical intraepithelial neoplasia (CIN), 95 cases of patients with clinical stage, 138 cases of patients with clinical stage Ⅱa, 124 cases of patients with clinical stage Ⅱb, 92 cases of patients with clinical stage Ⅲa, 69 cases of patients with clinical stage Ⅲb, 33 cases of patients with clinical stage IV of cervical carcinoma and 78 cases of healthy women as healthy control from September 2007 to September 2014 in Shaanxi Provincial Tumor Hospital were admitted and their peripheral blood CD3+ , CD4+ , CD8+ , CD4+ /CD8+ lymphocyte subsets and CD16+ CD56+ cells were detected by flow cytometry. Results Different patients with high-risk HPV infection in cervical lesions, CD4+ , CD16+ CD56+ cells and the numbers of CD4+ /CD8+ ratio were lower than those in the healthy control group, and with the severity of lesions increment to gradually reduce (P 0.05). But CD4+ , CD8+ cells and CD4+ /CD8+ ratio of patients with low differentiation are significantly lower than patients with well-differentiated. The number of cells of CD4+ , CD16+ CD56+ reducing and CD4+ /CD8+ ratio decreased were negative correlated to clinical stages of cervical carcinoma, namely were decreased with the increasing of clinical stages(P<0.01). The number of CD8+ cell was positive correlated with clinical stages of cervical carcinoma. (P<0.001). Conclusions The cellular immune function of the patients with high-risk HPV infection and different cervical lesions are lower and especially even worse in patients with cervical carcinoma and with advanced clinical stages. Detecting T lymphocyte subsets and NK immune cells can be used to monitor cellular immune function of patients with cervical carcinoma and to estimate prognosis and provide reference for clinical treatment. Key words: T lymphocyte subsets; NK cell; CIN; Cervix neoplasms; Papillomavirus, human